Platelet Recovery and Coexisting Conditions in Pediatric Immune Thrombocytopenia: Insights from a Tertiary Care Study

TL;DR

This study examines platelet recovery and coexisting conditions in children with immune thrombocytopenia at a tertiary care center.

Contribution

The study provides insights into clinical patterns and treatment outcomes in hospitalized children with newly diagnosed ITP.

Findings

Most children showed substantial platelet recovery with first-line therapy by hospital discharge.

Over 40% of patients were under 5 years old, and sex distribution varied by urban and rural residence.

Coexisting conditions were common but considered concurrent rather than causative.

Abstract

Background/Objectives: Immune thrombocytopenia (ITP) is a rare but significant hematologic disorder in children. While most pediatric ITP cases resolve spontaneously, some require intervention, and treatment responses with platelet recovery patterns can vary widely. We conducted a retrospective, three-year observational cohort study including 100 children (aged 5 months–17 years) diagnosed with ITP at a single tertiary center (January 2022–December 2024). The primary objective of this study was to characterize the clinical presentation, coexisting conditions, and short-term platelet response to first-line therapy in hospitalized children with newly diagnosed ITP. Methods: Clinical data (demographics, presentation, and laboratory results) were collected at admission and throughout hospitalization, and outcomes were assessed at discharge. Results: Our analysis showed a balanced urban–rural distribution overall; however, sex distribution differed by residence, with a slight female predominance in rural areas and an overwhelming male predominance in urban areas. Over 40% of patients were under 5 years old. Platelet counts at presentation ranged from 3 × 109/L to 30 × 109/L, yet nearly all children showed substantial platelet count recovery by hospital discharge under first-line therapy. Most patients had additional minor clinical findings at admission, but these were considered concurrent rather than causative factors, in accordance with current hematology guidelines. These conditions were considered coexisting clinical conditions or concurrent findings rather than definitive secondary causes of ITP, in accordance with established hematological guidelines. These findings reflect only short-term, in-hospital outcomes and may not be generalizable to all children with ITP, particularly milder or outpatient cases. Conclusions: Our three-year cohort study underscores that pediatric ITP often presents in very young children with concurrent conditions, but standard first-line treatment leads to robust platelet recovery by discharge. These findings highlight the importance of comprehensive initial evaluation and supportive care in managing pediatric ITP.

Figures